Veracyte Reports Q3 EPS Beat, Cuts FY26 Revenue Outlook, Plans Buyback

Veracyte reported Q3 earnings of $0.51 per share, excluding non-recurring items, $0.10 above the comparison cited in the headline. It also guided FY26 revenue below consensus and announced a buyback plan of up to $100 million.